Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drug

Rybelsus(Semaglutide)Novo Nordisk A/S logoNVO

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Novo Nordisk A/S

$1.89B

Medicare cost, 2024

Medicare drug plans spent $1.9 billion on Rybelsus (semaglutide) in 2024, for 1.3 million prescriptions and refills filled by 309,850 patients. It ranks 27th among all drugs by Medicare drug plan spending. California accounts for the most spending ($229.4 million, 12% of the total). It is made by Novo Nordisk A/S (NVO).

Medicare cost, 2024

$1.89B

+13.4% from 2023

Prescriptions

1.3M

$1,509.98 per claim

Patients

310K

125,776 prescribers

Total spending, 2024

$1.89B

$6,097.18 per patient

Questions and answers

How much does Medicare spend on Rybelsus?

Medicare prescription drug plans paid $1.89B for Rybelsus in 2024, for 1,251,182 prescriptions and refills to 309,850 patients (up 13.4% from 2023). The average cost per claim was $1,509.98.

Which state spends the most on Rybelsus?

California had the highest Medicare cost for Rybelsus in 2024: $229.4M for 157,307 claims, followed by New York ($171.6M).

Who prescribes Rybelsus the most?

Wei Y Sun, nephrology in New York, NY, had the highest Medicare cost for Rybelsus in 2024: 853 claims costing $872K.

Who makes Rybelsus?

Rybelsus is made by Novo Nordisk A/S (NVO), listed in the Medicare spending data as Novo Nordisk.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Rybelsus was $1.89B in 2024, the highest year shown.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Rybelsus, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Wei Y Sun New York, NYNephrology853127$872K
Yun Feng New York, NYEndocrinology719142$856K
Duc H Phan Houston, TXInternal Medicine521123$812K
George C Liu New York, NYInternal Medicine40194$768K
Phong H Bui Fountain Valley, CAInternal Medicine43187$633K
Ivana Sheu San Francisco, CAEndocrinology42984$613K
Sharon H Kim Bronx, NYEndocrinology36476$592K
Eliscer Guzman New York, NYInternal Medicine37797$563K
Bao Q Nguyen Stockton, CAFamily Practice58169$561K
Zihe Shan Brooklyn, NYInternal Medicine29770$541K
Michael W Lin San Gabriel, CAEndocrinology40279$535K
Sheikh M Masood Madera, CANephrology525109$518K
Isaiah Pittman IV Terre Haute, INEndocrinology374112$489K
Rodolfo Guzman Bronx, NYEndocrinology29667$480K
Bashar G Saad San Dimas, CAEndocrinology323101$475K
Tu N Truong San Diego, CAInternal Medicine26768$473K
Jerry L Jurado Union City, NJFamily Practice21265$472K
Manavendra Bakhshi Philadelphia, PACardiology40768$470K
Kathrine A Gold Brooklyn, NYInternal Medicine26966$469K
Enrique J Griego McAllen, TXFamily Practice28194$463K
Dinorah J Nutis El Paso, TXInternal Medicine20464$428K
Ashvin Vijayakumar Philadelphia, PAHospitalist37851$405K
Shailesh Baral York, PAEndocrinology26571$404K
Fufu He Brooklyn, NYFamily Practice26645$399K
Bosheng Qiu Alhambra, CAInternal Medicine37961$385K

Prescriber data by year

YearPrescribersClaimsPatientsCost
202281,128686,142184,563$974.6M
2023114,0751,074,653285,571$1.67B
2024125,7761,251,182309,850$1.89B

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Novo NordiskNVO logoNVO1,251,733$1.89B

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube